ADA 2021 | SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes | diabetes.medicinematters.com
Skip to main content

Home

Latest news

Browse topics

Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN

In focus

Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management

Congress coverage

EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions

About us

Medicine Matters Diabetes
EXTENDED SEARCH
Log in

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

share
SHARE

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

06-27-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials
Phase 3 trials of tirzepatide in type 2 diabetes and obesity
Image Credits